Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ultragenyx Pharmaceutical's Total Liabilities for the quarter that ended in Jun. 2026 was R$7,932 Mil.
Ultragenyx Pharmaceutical's quarterly Total Liabilities
declined
from Dec. 2025 (R$8,756.40 Mil) to Mar. 2026 (R$7,975.14 Mil) and
declined
from Mar. 2026 (R$7,975.14 Mil) to Jun. 2026 (R$7,932.11 Mil).
Ultragenyx Pharmaceutical's annual Total Liabilities
increased
from Dec. 2023 (R$5,956.19 Mil) to Dec. 2024 (R$7,571.34 Mil) and
increased
from Dec. 2024 (R$7,571.34 Mil) to Dec. 2025 (R$8,756.40 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Ultragenyx Pharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of R$7,932 Mil mean?
Ultragenyx Pharmaceutical (BSP:R2AR34) has a Total Liabilities of R$7,932 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Total Liabilities too high?
Ultragenyx Pharmaceutical's current Total Liabilities is R$7,932 Mil. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Total Liabilities compare to ATAI and QURE?
Ultragenyx Pharmaceutical's Total Liabilities of R$7,932 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Total Liabilities is R$7,932 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (BSP:R2AR34) is currently considered Possible Value Trap. The stock's GF Value™ is R$23.25, compared to a current price of R$12.87 — trading 44.6% below its estimated fair value. The current Total Liabilities is R$7,932 Mil. Ultragenyx Pharmaceutical's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (BSP:R2AR34), the current Total Liabilities is R$7,932 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (BSP:R2AR34) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of R$12.87 is trading 44.6% below its estimated GF Value™ of R$23.25.
GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.
Key valuation signals for BSP:R2AR34:
Total Liabilities: R$7,932 Mil
GF Value™: R$23.25 vs. price of R$12.87 (44.6% below fair value)
No single metric tells the full story. See the BSP:R2AR34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
43GF Score
Get the complete analysis for BSP:R2AR34
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:R2AR34 has been successfully added to your 
